Regulatory Assessment of Casgevy for the Treatment of Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-Occlusive Crises
Current Issues in Molecular Biology · 30.07.2024 · 46 (8) · 8209-8225
DOI: 10.3390/cimb46080485 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 30.07.2024. Verfasst von Essam Kerwash und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medicines and Healthcare Products Regulatory Agency (MHRA), 10 South Colonnade, London E14 4PU, UK. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are hereditary haemoglobinopathies characterized by a reduction in functional β-globin chains. Both conditions cause tiredness and increase susceptibility to infection, which can lead organ failure, significantly reducing life expectancy and typically requiring those affected to undergo regular erythrocyte transfusion. Recently, a novel therapeutic treatment for SCD and TDT was approved by the UK regulatory body (Medicines and Healthcare products Regulatory Agency; MHRA). Exagamglogene autotemcel (Casgevy) is the first licensed therapy globally to utilize CRIPSR/Cas9 technology and induces an increase in expression of γ-globin chains to compensate for the reduction in functional β-globin. Casgevy represents a first-in-class therapeutic, and numerous considerations were made by the MHRA throughout its assessment of the medicine. These include, but are not limited to, the risk of tumorigenicity and off-target editing, a limited cohort size, the validity of proposed dosing and the conduction of only single-arm studies. The MHRA’s analyses of the data to support the proposed indications are presented and discussed throughout this manuscript. Overall, the sponsors claims were considered well supported by their data, and Casgevy was licensed for the treatment of TDT or SCD in patients 12 years of age and older for whom hematopoietic stem cell (HSC) transplantation is appropriate, but a human leukocyte antigen-matched related HSC donor is not available.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medicines and Healthcare Products Regulatory Agency (MHRA), 10 South Colonnade, London E14 4PU, UK.
ORCID-Profile: Essam Kerwash, Marija Sajic, Andrew S Butler
Zitieren
APA
Kerwash, E., Sajic, M., Rantell, K. R., McBlane, J. W., Johnston, J. D., Niewiarowska, A., Butler, A. S., & Cole, S. (2024). Regulatory Assessment of Casgevy for the Treatment of Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-Occlusive Crises. Current Issues in Molecular Biology, 46(8), 8209-8225. https://doi.org/10.3390/cimb46080485
Vancouver
Kerwash E, Sajic M, Rantell KR, McBlane JW, Johnston JD, Niewiarowska A, et al. Regulatory Assessment of Casgevy for the Treatment of Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-Occlusive Crises. Current Issues in Molecular Biology. 2024;46(8):8209-8225. doi:10.3390/cimb46080485
BibTeX
@article{Kerwash2024,
author = {Kerwash, Essam and Sajic, Marija and Rantell, Khadija Rerhou and McBlane, James W and Johnston, John D and Niewiarowska, Alison and Butler, Andrew S and Cole, Susan},
title = {Regulatory Assessment of Casgevy for the Treatment of Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-Occlusive Crises},
journal = {Current Issues in Molecular Biology},
year = {2024},
volume = {46},
number = {8},
pages = {8209--8225},
doi = {10.3390/cimb46080485}
}
EUVIMED